NuVasive in Strong Position to Weather the COVID-19 Storm

NuVasive reported 1Q20 orthopedic revenue of USD $259.9 million, -5.4% vs. 1Q19. Sales performed to expectations through mid-March, but experienced a sharp decline that persisted through April due to the deferral of elective procedures. International sales growth was driven in large part by strength in Japan, but a state of emergency declared...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us